Plafibride treatment and serum lipids in hyperlipoproteinemias.
A study was made of 26 patients suffering from primary hyperlipoproteinemia; 8 belonging to familial hypercholesterolemia (phenotype IIa), 9 to familial combined hyperlipidemia (phenotype IIb, 9 to familial hypertriglyceridemia (phenotype IV). During treatment, which was continued for two years, all patients received a diet consisting of 45% carbohydrates, 33% fats and 22% protein. They were given 400 mg (TID) of Plafibride after breakfast, lunch and dinner. In the three phenotypes studied, significant decreases in cholesterol, triglycerides, glucose, insulin and lecithin were observed, while there was an increase in HDL cholesterol, free fatty acids and lysolecithin. Tolerance to the drug was good, and a study of different serum enzymes revealed no undesirable collateral effects.
Rodriguez
F
F
Medical Faculty of Valladolid, Spain.
López
I M
IM
Jover
E
E
D000293:Adolescent; D000328:Adult; D001786:Blood Glucose; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004032:Diet; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy*; D007328:Insulin / Q000097:blood; D008297:Male; D010713:Phosphatidylcholines / Q000097:blood; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D007328:Insulin; D010713:Phosphatidylcholines; D014280:Triglycerides; D002995:Clofibric Acid; C016894:plafibride; D002784:Cholesterol; D002994:Clofibrate